Diabetes Oral Medications/Anti-Diabetic Medications

Drugs used in diabetes treat diabetes mellitus by lowering glucose levels in the blood. With the exceptions of Insulin, exenatide, liraglutide and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and situation of the person, as well as other factors.
Diabetes mellitus type 1 is a disease caused by the lack of insulin. Insulin must be used in Type I, which must be injected.
Diabetes mellitus type 2 is a disease of insulin resistance by cells. Type 2 diabetes mellitus is the most common type of diabetes. Treatments include (1) agents that increase the amount of insulin secreted by the pancreas, (2) agents that increase the sensitivity of target organs to insulin, and (3) agents that decrease the rate at which glucose is absorbed from the gastrointestinal tract.
Several groups of drugs, mostly given by mouth, are effective in Type II, often in combination. Insulin sensitizers address the core problem in Type II diabetes—insulin resistance.
Thiazolidinediones (TZDs), also known as "glitazones," bind to PPARγ, a type of nuclear regulatory protein involved in transcription of genes regulating glucose and fat metabolism.
Secretagogues are drugs that increase insulin output from the pancreas. Meglitinides help the pancreas produce insulin and are often called "short-acting secretagogues".
Alpha-glucosidase inhibitors are "diabetes pills" but not technically hypoglycemic agents because they do not have a direct effect on insulin secretion or sensitivity. Dipeptidyl peptidase-4 (DPP-4) inhibitors increase blood concentration of the incretin GLP-1 by inhibiting its degradation by dipeptidyl peptidase-4.

  • Meglitinides – nateglinide (Nonsulfonylurea secretagogues)
  • Biguanides – metformin (Insulin Sensitizers)
  • Sulfonylureas - glimepiride, glipizide, glyburide ( Secretagogues)
  • Thiazolidinediones (Tzd) – pioglitazone (Insulin Sensitizers)
  • Alpha-glucosidase inhibitors – Acarbose (Diabetes Pills)
  • Injectable Incretin mimetics
  • Injectable Amylin analogues
  • Glycosurics (sodium/glucose cotransporter 2 (SGLT2)Inhibitors)

Related Conference of Diabetes Oral Medications/Anti-Diabetic Medications

February 24-25, 2025

34th European Diabetes Congress

London, UK
March 10-11, 2025

4th Global Summit on Physiology and Metabolism of Thyroid

Singapore City, Singapore
March 17-18, 2025

5th European Endocrinology and Diabetes Congress

Paris, France
April 10-11, 2025

5th World Congress on Endocrine and Diabetes

Dubai, UAE
April 10-11, 2025

4th International Summit on Hormonal Disorders

Dubai, UAE
May 19-20, 2025

6th World Summit on Diabetes

Rome, Italy
June 04-05, 2025

4th World Congress on Diabetes and Pediatric Endocrinology

Edinburgh, Scotland
July 29-30, 2025

15th World Congress on Endocrinology and Diabetes

Aix-en-Provence, France
September 08-09, 2025

3rd World congress and Expo on Diabetes

Frankfurt, Germany
November 20-21, 2025

21st World Congress on Endocrinology & Diabetes

Aix-en-Provence, France

Diabetes Oral Medications/Anti-Diabetic Medications Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in